Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2014; 20(44): 16774-16778
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16774
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16774
Case report of acute-on-chronic liver failure secondary to diffuse large B-cell lymphoma
Yahuza Siba, Kenechukwu Obiokoye, Department of Medicine, Columbia University Medical Center, Harlem Hospital Center, New York, NY 10037, United States
Richard Ferstenberg, James Robilotti, Joan Culpepper-Morgan, Division of Gastroenterology, Department of Medicine, Columbia University Medical Center, Harlem Hospital Center, New York, NY 10037, United States
Author contributions: Siba Y and Obiokoye K are the residents who managed the case as well as drafting the article; Ferstenberg R and Robilotti J helped write and edit the manuscript; Culpepper-Morgan J supervised, proof-read and made all the necessary corrections required; all the authors reviewed and agreed on the final manuscript.
Correspondence to: Yahuza Siba, MD, Department of Medicine, Columbia University Medical Center, Harlem Hospital Center, 506 Lenox Avenue, New York, NY 10037, United States. sy2394@columbia.edu
Telephone: +1-212-9392296 Fax: +1-212-9392263
Received: May 31, 2014
Revised: August 4, 2014
Accepted: September 29, 2014
Published online: November 28, 2014
Revised: August 4, 2014
Accepted: September 29, 2014
Published online: November 28, 2014
Core Tip
Core tip: Recognition of acute on chronic liver failure (ACLF) is vital because it may be rapidly fatal. However, many patients have underlying silent liver disease, especially, hepatitis C virus (HCV) cirrhosis. Diffuse large B-cell lymphoma is an aggressive lymphoma which is beginning to occur more frequently in the same race and birth cohort as HCV/human immunodeficiency virus related liver disease. Early recognition and potential treatment of this rapidly fatal lymphoma depends on a high index of suspicion. Due to the shared demographics the incidence of non-Hodgkin’s lymphoma presenting as ACLF is likely to increase.